A two phases post authorization safety and effectiveness study of individuals vaccinated with the MF59-adjuvanted A/H1N1 influenza vaccine, Focetria® (Novartis Vaccines & Diagnostics, Siena, Italy), was conducted in Emilia-Romagna regItalyItaly during the 2009 A/H1N1 influenza pandemic.
The draft rules, which still need to be approved by Parliament as a whole and the Council of Ministers, would subject novel foods to safety evaluation and authorization via a fully harmonized EU-wide procedure.
This is not possible for the data used as a proof of safety for commercial authorizations.
This non-interventional post-authorization safety study (PASS) is a phase IV commitment to the FDA.
The approach has been developed in parallel with the new legislative requirement for pharmaceutical companies to undertake a risk management plan as part of post-authorization safety monitoring.
The evolving regulatory landscape has heightened the need for innovative, proactive, efficient and more meaningful solutions for 'real-world' post-authorization safety studies (PASS).
Recently, the term "post-authorization safety studies" (PASS) was incorporated into European law, and these studies are now closer to NIS [ 40, 41].
The Scandinavian ONJ Cohort was established to support an ongoing regulator-mandated post-authorization safety study (PASS) of denosumab, 120 mg every 4 weeks, in Denmark, Norway, and Sweden, with clinically confirmed ONJ as a primary safety endpoint.
In addition to the increased emphasis on B/R assessments, the ICH proposes a modular design to facilitate differences in international reporting requirements and a greater harmonization with pre-authorization safety reports.
The DACCORD study should also provide both post-authorization safety study (PASS) data for the European Medicine Agency EMAA) if needed and real life effectiveness data on pharmacologic treatment in accordance with guidelines.
